TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00577889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: 154 mg/m2 Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: 154 mg/m2 Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: 154 mg/m2 Given IV
Study: NCT02077452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Study: NCT03008447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBO
Description: Single dose of placebo administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBO
Description: Single dose of placebo administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBO
Description: Single dose of placebo administered within 5 minutes before bedtime.
Study: NCT02231853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVST
Description: MVST Infusion
Study: NCT02077452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02077452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02874378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%NaCl solution
Study: NCT03054532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab intravenous 1500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenali
Description: Lenalidomide oral 20 mg/day
Study: NCT02507232

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-200A
Description: 12 cycles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-200A
Description: 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
Study: NCT04586439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered (high or low dose) as single SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered (high or low dose) as single SC injection.
Study: NCT03183869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota
Description: fecal microbial transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota
Description: fecal microbial transplantation
Study: NCT02826070

Intervention type: DRUG
Group type: OTHER
Intervention: Telbivudine
Description: Telbivudine, 600mg, oral, daily

Intervention type: DRUG
Group type: OTHER
Intervention: Adefovir dipivoxil
Description: Adefovir dipivoxil 10mg, oral, daily

Intervention type: OTHER
Group type: OTHER
Intervention: off-treatment follow-up
Study: NCT04171843

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PBCAR269A
Description: Allogeneic anti-BCMA CAR T-cell
Study: NCT02231853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVST
Description: MVST Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVST
Description: MVST Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVSTr
Description: PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.~Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVSTr
Description: PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.~Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr.
Study: NCT01019317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 0.5 grams/m\^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients \> 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 15 mg/m\^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients \> 65 years and 3 days in patients with PS \> 3).
Study: NCT03780426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tSMS
Description: Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tSMS
Description: Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham
Description: A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham
Description: A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.
Study: NCT01037881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 29102
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel®
Description: comparison
Study: NCT04474223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: In mother in whom 2° AVB or AV interval \>170 ms has been diagnosed in the fetus:~Dexamethasone 8 mg po/day for 10 days. Then dexamethasone 4 mg po/ day through 28 weeks 6 days gestational age (GA); then 3 mg/day from 29 wks 0 days to 29 wks 6 days GA; then 2 mg/day until delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: In a mother in whom 2° AVB has been diagnosed in the fetus:~One dose of IVIG \[1g/kg of maternal weight (max dose 70 g)\] at diagnosis of 2° AVB (within 12 hours of detection by mother via home monitoring and within 6 hours of confirmation by echocardiogram). A fetal AV interval \> 170 ms will not be treated with maternal IVIG, only dexamethasone.
Study: NCT00458809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin
Study: NCT01326533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirteen weeks of oral placebo provided as capsules
Study: NCT00477854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromium Picolinate
Description: Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromium Picolinate
Description: Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
Study: NCT00628251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: 400mg Oral twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Doxorubicin
Description: 50mg/m2 Monthly Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: 200mg oral twice daily
Study: NCT02622880

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: immunomodulatory supplement
Description: Experimental Group (immunomodulatory supplement STUDY)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IMPACT
Description: IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
Study: NCT04046133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.
Study: NCT01971203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seroquel xr
Description: Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: 16 weeks of treatment
Study: NCT02166866

Intervention type: OTHER
Intervention: Quality of Life Questionairre and Education
Study: NCT02037646

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative fecal immunochemical test
Description: This test measures the amount of blood within the submitted stool specimen

Intervention type: OTHER
Group type: OTHER
Intervention: Quantitative fecal immunochemical test
Description: This test detects presence or absence of blood within a submitted stool specimen.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.

Intervention type: OTHER
Group type: OTHER
Intervention: Cost analysis
Description: Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.

Intervention type: OTHER
Group type: OTHER
Intervention: Cost analysis
Description: Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.

Intervention type: OTHER
Group type: OTHER
Intervention: Anxiety scores
Description: Hospital Anxiety and Depression Scale (HADS) questionnaire
Study: NCT04171843

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PBCAR269A
Description: Allogeneic anti-BCMA CAR T-cell

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PBCAR269A
Description: Allogeneic anti-BCMA CAR T-cell
Study: NCT02037646

Intervention type: OTHER
Group type: OTHER
Intervention: Anxiety scores
Description: Hospital Anxiety and Depression Scale (HADS) questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Patient satisfaction scores
Description: A 5-point patient satisfaction score will be documented at each patient visit related to screening.

Intervention type: OTHER
Group type: OTHER
Intervention: Patient satisfaction scores
Description: A 5-point patient satisfaction score will be documented at each patient visit related to screening.
Study: NCT00728481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose \[Splenda-registered trademark\]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
Study: NCT00954525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Erlotinib
Description: Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C
Description: 50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
Study: NCT02645513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Malaria text message reminders to health workers
Description: Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Malaria, pneumonia, and diarrhea text message reminders to health workers
Description: Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No text message reminders
Study: NCT02873507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI of donor liver prior to transplant
Description: MRI of the on ice donor liver within the transport cooler on its way to the operating room
Study: NCT02906839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI \>15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
Study: NCT00350805

Intervention type: PROCEDURE
Intervention: EEG
Description: One 20 minutes session

Intervention type: PROCEDURE
Intervention: EEG
Description: One 20 minutes session
Study: NCT01832363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HXe MRI guided treatment sequence for BT
Description: HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment sequence for BT (control)
Description: Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
Study: NCT00778622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
Study: NCT03641053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey
Description: Substance is given topically after the wound has been sutured

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine
Description: Substance is given topically after the wound has been sutured

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin gauze
Description: Substance is given topically after the wound has been sutured
Study: NCT02831205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everolimus-eluting bioresorbable vascular (Absorb) scaffold

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: everolimus-eluting cobalt-chromium (Xience) stent
Study: NCT04003935

Intervention type: OTHER
Intervention: Juice Plus+ Complete
Description: Plant-based smoothie; maintaining habitual diet.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Juice Plus+ Premium
Description: Fruit and vegetable juice concentrate; maintaining habitual diet.
Study: NCT00078754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine capsules by mouth, up to 60 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: Divalproex ER capsules by mouth, up to 3000 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules by mouth, up to 8 capsules daily
Study: NCT00147823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vitoss Alone
Description: Synthetic bone graft material

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitoss with Bone Marrow Aspirate
Description: Vitoss mixed with Bone Marrow aspirate
Study: NCT01968070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY3127760
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127760
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127760
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3127760
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3127760
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02823626

Intervention type: DRUG
Intervention: Spironolactone and patiromer
Description: High dose spironolactone with or without patiromer based on the patient's baseline potassium
Study: NCT00775450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.5 mL, Intramuscular
Study: NCT04171843

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PBCAR269A
Description: Allogeneic anti-BCMA CAR T-cell

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PBCAR269A
Description: Allogeneic anti-BCMA CAR T-cell

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PBCAR269A
Description: Allogeneic anti-BCMA CAR T-cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.
Study: NCT00775450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.5 mL, Intramuscular
Study: NCT03655379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal nasal Doppler by ultrasonography
Description: Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns and measurements will be performed